Robert W. Baird analyst Michael Ulz maintained a Buy rating on Amicus (NASDAQ:FOLD) Therapeutics on Monday, setting a price target of $18, which is approximately 52.67% above the present share price of $11.79.
Ulz expects Amicus Therapeutics to post earnings per share (EPS) of -$0.25 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Amicus, with an average price target of $18.17.
The analysts price targets range from a high of $29 to a low of $12.5.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.44 million and a net profit of -$51.73 million. The company's market cap is $3.2 billion.
According to TipRanks.com, Robert W. Baird analyst Michael Ulz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.6% and a 51.61% success rate.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.